{"classes":[{"categories":[{"measurements":[{"comment":"upper limit is not reached.","groupId":"OG000","lowerLimit":"5.5","upperLimit":"NA","value":"12.9"},{"comment":"upper limit is not reached.","groupId":"OG001","lowerLimit":"3.8","upperLimit":"NA","value":"5.6"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"8.2","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"137"}],"units":"Participants"}],"description":"Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1).","dispersionType":"Inter-Quartile Range","groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"OG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"OG001","title":"Monotherapy"},{"description":"Standard of Care Chemotherapy Treatment","id":"OG002","title":"Standard of Care"}],"paramType":"MEDIAN","populationDescription":"The PD-L1-Low/Negative analysis set will include the subset of patients in the FAS whose PD-L1 status is PD-L1-Low/negative as defined by an Immunohistochemistry (IHC) assay developed by Ventana as:\n\n\\<25% tumor cell membrane positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control AND \\<25% tumor associated immune cell positivity for PD-L1 at any intensity above background staining as noted on the corresponding negative control.","reportingStatus":"POSTED","timeFrame":"Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).","title":"Duration of Response (DoR), PD-L1-Low/Negative Analysis Set","type":"SECONDARY","unitOfMeasure":"Months"}